Refining Therapy in Patients with HER2-Positive Breast Cancer with Central Nervous System Metastasis.

Marta Filipa Freire Vaz Batista, Inês Eiriz, Amanda Fitzpatrick, Fanny Le Du, Sofia Braga, Diogo Alpuim Costa

Open access · greenAbstract readReview

In one paragraph

Review in Breast care (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 50% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

Evolution of HER2 Targeting in Metastatic Breast Cancer.Breast care (Basel, Switzerland) · 2022
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Marta Filipa Freire Vaz BatistaOncology Department, Hospital Professor Doutor Fernando Fonseca EPE, Amadora, Portugal.

Inês EirizOncology Department, Hospital Professor Doutor Fernando Fonseca EPE, Amadora, Portugal.

Amanda FitzpatrickOncology Department, Guy's and St Thomas' Hospital, London, UK.

Fanny Le DuOncology Department, CRLCC Eugène Marquis, Rennes, France.

Sofia BragaOncology Department, Hospital Professor Doutor Fernando Fonseca EPE, Amadora, Portugal.

Diogo Alpuim CostaHaematology and Oncology Department, CUF Oncologia, Lisbon, Portugal.

Hospital Prof. Dr. Fernando Fonseca · PTCentre Eugène Marquis · FRSt Thomas' Hospital · GB

Funding

Medical Research Council MR/P001564/1

6 · The paper itself

Abstract

Background: Brain metastasis (BM) is a major clinical problem in metastatic breast cancer (MBC), occurring in 50% of patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Historically omitted from clinical trials, recent studies of novel HER2-targeted agents have focused on HER2+ BM patients, addressing stable but also progressing BM and leptomeningeal carcinomatosis (LMC). Summary: This review aimed to summarize the most relevant data on treating patients with HER2+ BM and LMC. Key Messages: The treatment paradigm for patients with HER2+ MBC has changed. Local therapies play an important role, but accumulating evidence on the intracranial activity and clinical benefit of anti-HER2 targeting therapies might lead to a shift in the paradigm on treating BM in the next few years towards more widespread use of systemic therapy.

Indexed as

Anti-HER2-targeted therapyBrain metastasisCentral nervous system metastasisHuman epidermal growth factor receptor-type 2-positive breast cancerLeptomeningeal carcinomatosis

Identifiers

PMID36590149

DOI10.1159/000526431

PMCPMC9801402

OpenAlexW4292572070

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.